Therapy News and Research

RSS

FDA approves CSL Behring's Hizentra for PI

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

4 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

A new study, led by researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, demonstrates that acupuncture may be an effective therapy for joint pain and stiffness in breast cancer patients who are being treated with commonly used hormonal therapies. Results were published in the Journal of Clinical Oncology.

4 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Top ten beauty treatments

RoxSpa, one of the most prestigious and luxurious medi-spas in Beverly Hills, announces their annual 'Top Ten' face and body rejuvenation treatments that are both highly-effective and provide the most satisfying results.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Back injury can set you on your back and set you back financially

Whether you're doing heavy lifting as part of your "honey-do list" around the house or simply lifting groceries out of the car, a back injury can set you on your back (literally) and set you back financially. According to a tally of accident insurance claims submitted in 2009 to Colonial Life & Accident Insurance Company, back sprain or strain was the number-one occurring injury.

4 Mar 2010

MIT Technology Review recognizes Medtronic for taking leadership in developing DBS Therapy

Medtronic, Inc. today announced that it has been selected as one of Massachusetts Institute of Technology Technology Review's 50 most innovative companies. Known as TR50, the first annual list includes companies that Technology Review believes have demonstrated superiority in inventing technology and in using it both to grow their own business and transform how we live.

4 Mar 2010

Project ProSPECTus develops technology for next generation SPECT imaging to improve diagnosis of cancer

Time taken to detect brain tumours could soon be significantly reduced thanks to an ongoing pioneering project led by the University of Liverpool with the Nuclear Physics Group and Technology departments at the Science and Technology Facilities Council (STFC) at Daresbury Laboratory.

4 Mar 2010

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy.

4 Mar 2010

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Researchers in the US and Denmark have made a breakthrough in image-guided targeting of prostate tumors during arc radiotherapy treatments. In research partially supported by Varian Medical Systems, physicists at Stanford University (California, USA) and Aarhus University Hospital (Aarhus, Denmark) have devised a method for 'real-time' tracking of the prostate motion using Varian's On-Board Imager® that shows promise in paving the way for advanced clinical treatments.

4 Mar 2010

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

4 Mar 2010

Clear One Health Plans launches Natural Health Plan for Oregon residents

Clear One Health Plans, Inc. today announced the launch of the first Natural Health Plan that focuses on holistic health insurance available in the state of Oregon. The new Natural Health Plan is available throughout the state of Oregon beginning February 1, 2010 to Oregon residents and is specifically designed with an emphasis on alternative medicine such as naturopathic medicine, chiropractic, acupuncture, massage therapy, and nutraceuticals (vitamins and minerals).

4 Mar 2010

Researchers demonstrate the safety of potential vaccine against mesothelioma

Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Gene therapy for LCA clears another hurdle: Study

Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle. The same research team that conducted the human trial now reports that a study in animals has shown that a second injection of genes into the opposite, previously untreated eye is safe and effective, with no signs of interference from unwanted immune reactions following the earlier injection.

4 Mar 2010

St. Jude Medical publishes clinical results of HOMEOSTASIS trial

St. Jude Medical, Inc. today announced publication of clinical results in the Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) trial.

4 Mar 2010

MHAUS introduces new MH Mock Drill Training Kit to better prepare for MH emergencies

The Malignant Hyperthermia Association of the United States introduces a new MH Mock Drill Training Kit for Operating Room Staff to better prepare for MH emergencies

4 Mar 2010

Therapy News and Research

FDA approves CSL Behring's Hizentra for PI

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Top ten beauty treatments

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Back injury can set you on your back and set you back financially

MIT Technology Review recognizes Medtronic for taking leadership in developing DBS Therapy

Project ProSPECTus develops technology for next generation SPECT imaging to improve diagnosis of cancer

TNFerade's suppression of cancer metastases: Mechanisms revealed

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Clear One Health Plans launches Natural Health Plan for Oregon residents

Researchers demonstrate the safety of potential vaccine against mesothelioma

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Gene therapy for LCA clears another hurdle: Study

St. Jude Medical publishes clinical results of HOMEOSTASIS trial

MHAUS introduces new MH Mock Drill Training Kit to better prepare for MH emergencies

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News